Systematic Review and Meta‐Analysis of Pharmacological Therapies for Painful Diabetic Peripheral Neuropathy
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background: Painful diabetic peripheral neuropathy (pDPN) is prevalent among persons with diabetes and increases over time. Published guidelines recommend a number of medications to treat this condition providing clinicians with a variety of treatment options. This study provides a comprehensive systematic review and meta‐analysis of published pharmacologic therapies for pDPN. Methods: The published literature was systematically searched to identify randomized, controlled trials of all available pharmacologic treatments for pDPN (recommended or nonrecommended) reporting predefined efficacy and safety outcomes. Bayesian fixed‐effect mixed treatment comparison methods were used to assess relative therapeutic efficacy and harms. Results: Data from 58 studies including 29 interventions and 11,883 patients were analyzed. Pain reduction over that of placebo on the 11‐point numeric rating scale ranged from −3.29 for sodium valproate (95% credible interval [CrI] = [−4.21, −2.36]) to 1.67 for Sativex (−0.47, 0.60). Estimates for most treatments were clustered between 0 and −1.5 and were associated with more study data and smaller CrIs. Pregabalin (≥ 300 mg/day) was the most effective on the 100‐point visual analog scale (−21.88; [−27.06, −16.68]); topiramate was the least (−3.09; [−3.99, −2.18]). Relative risks (RR s) of 30% pain reduction ranged from 0.78 (Sativex) to 1.84 (lidocaine 5% plaster). Analysis of the RR ratio of these 2 treatments reveals marginal significance for Sativex (3.27; [1.07, 9.81]), indicating the best treatment is only slightly better than the worst. Relative risks of 50% pain reduction ranged from 0.98 (0.56, 1.52) (amitriptyline) to 2.25 (1.51, 3.00) (alpha‐lipoic acid). RR ratio for these treatments was not statistically different (3.39; [0.88, 3.34]). Fluoxetine had the lowest risk of adverse events (0.94; [0.62, 1.23]); oxycodone had the highest (1.55; [1.45, 1.64]). Discontinuation RR s were clustered around 0.8 to 1.5, with those on the extreme having greater uncertainty. Conclusions: Selecting an appropriate pDPN therapy is key given the large number of available treatments. Comparative results revealed relative equivalence among many of the studied interventions having the largest overall sample sizes and highlight the importance of standardization of methods to effectively assess pain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Core outcome measures for chronic pain clinical trials: IMMPACT recommendations
Dworkin, R. H., Turk, D. C., Farrar, J. T., Haythornthwaite, J. A., Jensen, M. P., Katz, N. P., Kerns, R. D., Stucki, G., Allen, R. R., Bellamy, N., et al. (2005) · Pain · doi:10.1016/j.pain.2004.09.012 · Cited by 3,732
EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision
Attal, N., Cruccu, G., Baron, R., Haanpää, M., Hansson, P., Jensen, T. S., & Nurmikko, T. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.02999.x · Cited by 1,873
Chou, R., Carson, S., & Chan, B. K. S. (2009) · Journal of General Internal Medicine · doi:10.1007/s11606-008-0877-5 · Cited by 57
Cited by
Diabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and Pharmacotherapy
Iqbal, Z., Azmi, S., Yadav, R., Ferdousi, M., Kumar, M., Cuthbertson, D. J., Lim, J., Malik, R. A., & Alam, U. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.04.001 · Cited by 487
“A meta-analysis reported that the 5% lidocaine patch was as efficacious as pregabalin in treating painful DPN.(134) Topical isosorbide dinitrate has been evaluated in the treatment of painful DPN.”
MethodDiabetic neuropathic pain: Physiopathology and treatment
Schreiber, A. K. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i3.432 · Cited by 463
Slangen, R., Schaper, N. C., Faber, C. G., Joosten, E. A., Dirksen, C. D., van Dongen, R. T., Kessels, A. G., & van Kleef, M. (2014) · Diabetes Care · doi:10.2337/dc14-0684 · Cited by 264
Treating pain in diabetic neuropathy: current and developmental drugs
Alam, U., Sloan, G., & Tesfaye, S. (2020) · Drugs · doi:10.1007/s40265-020-01259-2 · Cited by 104
“Another systematic review and meta-analysis has also reported similar efficacy with pregabalin to the 5% lidocaine patch [83].”
BackgroundArnold, L. M., McCarberg, B. H., Clair, A. G., Whalen, E., Thomas, N., Jorga, A., Pauer, L., Vissing, R., & Park, P. W. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1384691 · Cited by 27
Metadata
- Authors
- Snedecor, S. J., Sudharshan, L., Cappelleri, J. C., Sadosky, A., Mehta, S., & Botteman, M.
- Venue
- Pain Practice
- Publisher
- Wiley
- Published
- 2013-03-28
- Volume
- 14
- Issue
- 2
- Pages
- 167-184
- ISSN
- 1530-7085 (ISSN-L)
- 1533-2500
- OpenAlex
- W2058221158
- Cited by
- 127
- References
- 3
- FWCI
- 2.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.